Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
50%(3 trials)

Phase Distribution

Ph phase_2
1
17%
Ph phase_3
2
33%
Ph phase_4
1
17%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
2(50.0%)
Phase 4Post-market surveillance
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 32 (50.0%)
Phase 41 (25.0%)

Trials by Status

completed6100%

Recent Activity

0 active trials
Showing 5 of 6
completed

Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs

NCT04696042
completedphase_3

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

NCT04852679
completed

Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands

NCT06607666
completedphase_4

Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy

NCT01070758
completedphase_2

Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction

NCT02275338
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04696042

Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs

Completed
NCT04852679Phase 3

Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

Completed
NCT06607666

Acromegaly Resistant to Conventional Dose of First Generation Somatostatin Ligands

Completed
NCT01070758Phase 4

Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy

Completed
NCT02275338Phase 2

Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction

Completed
NCT02493517Phase 3

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6